Pharma major Lupin announced the launch of its Carbidopa Tablets 25mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Carbidopa Tablets, 25mg is the generic equivalent of Aton Pharma, Inc.’s Lodosyn® Tablets, 25 mg. It is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.